Search results for: Peter M.A. Calverley

Items from 1 to 20 out of 37 results

article

Home economics for COPD care

Peter M.A. Calverley

Respirology > 25 > 2 > 124 - 125

See related Article

article

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Philip D. Adamson, Julie A. Anderson, Robert D. Brook, Peter M.A. Calverley, more

Journal of the American College of Cardiology > 2018 > 72 > 10 > 1126-1137

Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular events.This study evaluated the association between high-sensitivity cardiac troponin I concentration and cardiovascular events in patients with COPD and heightened cardiovascular risk.In a double-blind randomized controlled trial, 16,485 patients with COPD and cardiovascular disease or risk factors were...

article

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Andrew P. Holmes, more

Respiratory Medicine > 2017 > 131 > C > 27-34

Pneumonia risk with inhaled corticosteroid use in chronic obstructive pulmonary disease (COPD) has not been thoroughly assessed in patients with moderate airflow limitation.To determine the incidence of pneumonia and risk factors in COPD patients with moderate airflow limitation who had, or were at high risk for cardiovascular disease.In the Study to Understand Mortality and MorbidITy in COPD (SUMMIT),...

article

Where to start when treating COPD?

Peter M.A. Calverley

Respirology > 22 > 7 > 1239 - 1240

See related Article

article

PROGNOSTIC IMPORTANCE OF BLOOD PRESSURE AND HEART RATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE SUMMIT TRIAL

James Brian Byrd, David E. Newby, Julie A. Anderson, Peter M.A. Calverley, more

Journal of the American College of Cardiology > 2017 > 69 > 11(S) > 1764

article

HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL

Nicholas L. Mills, Julie A. Anderson, Robert D. Brook, Peter M.A. Calverley, more

Journal of the American College of Cardiology > 2017 > 69 > 11(S) > 1819

article

Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study

Vasileios Andrianopoulos, Bartolome R. Celli, Frits M.E. Franssen, Victor M. Pinto-Plata, more

Respiratory Medicine > 2016 > 119 > C > 87-95

Exercise-induced oxygen desaturation (EID) is related to mortality in patients with chronic obstructive pulmonary disease (COPD). We investigated: (1) the prevalence of EID; (2) the relative-weight of several physiological determinants of EID including pulmonary emphysema, and (3) the relationship of EID with certain patients' clinical characteristics.Data from 2050 COPD patients (age: 63.3 ± 7.1years;...

article

Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease

Pavol Joppa, Ruzena Tkacova, Frits M.E. Franssen, Corrine Hanson, more

Journal of the American Medical Directors Association > 2016 > 17 > 8 > 712-718

Both loss of muscle mass (ie, sarcopenia) and obesity adversely impact clinically important outcomes in patients with chronic obstructive pulmonary disease (COPD). Currently, there are only a few studies in patients with COPD with sarcopenia and concurrent obesity, termed sarcopenic obesity (SO).To explore the effects of SO on exercise capacity, health status, and systemic inflammation in COPD.Baseline...

article

Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale

Helgo Magnussen, Henrik Watz, Anne Kirsten, Marc Decramer, more

Respiratory Medicine > 2014 > 108 > 4 > 593-599

Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are recommended to decrease the risk of recurrent exacerbations in patients with Global initiative for chronic Obstructive Lung Disease (GOLD) stage 3–4 chronic obstructive pulmonary disease (COPD). There is increasing concern about the clinical benefit and long-term safety of ICS use in COPD patients. The WISDOM (Withdrawal...

article

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD

Nicola A. Hanania, Peter M.A. Calverley, Mark T. Dransfield, Jill P. Karpel, more

Respiratory Medicine > 2014 > 108 > 2 > 366-375

This post-hoc analysis examined the impact of roflumilast on chronic obstructive pulmonary disease (COPD) exacerbations and lung function in patients with COPD who received concomitant long-acting β ₂ -agonists (LABA) with or without prior inhaled corticosteroid (ICS) and the influence of various demographic and clinical characteristics on these outcomes.Data were pooled from 2 double-blind,...

article

Corrigendum to “Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial” [Respir Med 107 (2013) 550–559]

Fernando J. Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, more

Respiratory Medicine > 2013 > 107 > 12 > 2092-2093

article

Measuring habitual physical activity in adults with cystic fibrosis

Daniela Savi, Serena Quattrucci, Mattia Internullo, Riccardo V. De Biase, more

Respiratory Medicine > 2013 > 107 > 12 > 1888-1894

The aim of the present study was to determine whether different methods of recording physical activity (PA), i.e., accelerometers vs questionnaires, provided similar information in adults with cystic fibrosis (CF).20 CF (age 33 ± 8SD yrs, FEV ₁ 68 ± 16% predicted) and 11 age-matched healthy controls completed the Habitual Activity Estimation Scale (HAES) questionnaire and wore a biaxial accelerometer...

article

Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations

Peter MA Calverley, Paul Albert, Paul P Walker

The Lancet Respiratory Medicine > 2013 > 1 > 7 > 564-573

The change in forced expiratory volume in 1 s (FEV₁) after administration of a short-acting bronchodilator has been widely used to identify patients with chronic obstructive pulmonary disease (COPD) who have a potentially different disease course and response to treatment. Despite the apparent simplicity of the test, it is difficult to interpret or rely on. Test performance is affected by the day...

article

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

Joy Miller, Lisa D. Edwards, Alvar Agustí, Per Bakke, more

Respiratory Medicine > 2013 > 107 > 9 > 1376-1384

Comorbidities, are common in COPD, have been associated with poor outcomes and are thought to relate to systemic inflammation. To investigate comorbidities in relation to systemic inflammation and outcomes we recorded comorbidities in a well characterized cohort (ECLIPSE study) for 2164 clinically stable COPD subjects, 337 smokers and 245 non-smokers with normal lung function.COPD patients had a higher...

article

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials

Mark T Dransfield, Jean Bourbeau, Paul W Jones, Nicola A Hanania, more

The Lancet Respiratory Medicine > 2013 > 1 > 3 > 210-223

Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β ₂ agonist is more protective than a once-daily longacting β ₂ agonist alone against exacerbations of chronic obstructive pulmonary disease (COPD) is unknown. We hypothesised that fluticasone furoate and vilanterol would prevent more exacerbations than would vilanterol alone. We did two...

article

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial

Fernando J. Martinez, Joseph Boscia, Gregory Feldman, Catherine Scott-Wilson, more

Respiratory Medicine > 2013 > 107 > 4 > 550-559

Once-daily combination treatment is an attractive maintenance therapy for COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is unknown. We compared two strengths of fluticasone furoate (FF) plus vilanterol (VI), the same strengths of the individual components, and placebo.Multicentre, randomised, 24-week, double-blind, placebo-controlled, parallel-group study in...

article

Factors associated with change in exacerbation frequency in COPD

Gavin C Donaldson, Hanna Müllerova, Nicholas Locantore, John R Hurst, more

Respiratory Research > 2013 > 14 > 1 > 1-9

Background Patients with chronic obstructive pulmonary disease (COPD) can be categorized as having frequent (FE) or infrequent (IE) exacerbations depending on whether they respectively experience two or more, or one or zero exacerbations per year. Although most patients do not change category from year to year, some will, and the factors associated with this behaviour have not been examined. Methods...

article

Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study

Benjamin Waschki, Martijn A. Spruit, Henrik Watz, Paul S. Albert, more

Respiratory Medicine > 2012 > 106 > 4 > 522-530

Little is known about COPD patients’ compliance with physical activity monitoring and how activity relates to disease characteristics in a multi-center setting.In a prospective study at three Northern European sites physical activity and clinical disease characteristics were measured in 134 COPD patients (GOLD-stage II–IV; BODE index 0–9) and 46 controls. Wearing time, steps per day, and the physical...

article

Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease

Martijn A. Spruit, Michael I. Polkey, Bartolome Celli, Lisa D. Edwards, more

Journal of the American Medical Directors Association > 2012 > 13 > 3 > 291-297

Exercise tolerance is an important clinical aspect of chronic obstructive pulmonary disease that can be easily and reliably measured with the 6-minute walking test (6MWT). To improve the utility of the 6MWT for patient and health care system management, the interpretation of the functional status measure in relation to death and hospitalization should be elucidated.Three-year, prospective, multicenter...

article

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

Paul W Jones, Julie A Anderson, Peter Ma Calverley, Bartolome R Celli, more

Respiratory Research > 2011 > 12 > 1 > 1-8

Background Little is known about factors that determine health status decline in clinical trials of COPD. Objectives To examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate (SFC) vs. salmeterol alone, fluticasone propionate alone or placebo. Methods St George's Respiratory Questionnaire (SGRQ) was administered at baseline then every 6 months. Measurements...

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Peter M.A. Calverley

Home economics for COPD care

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial

Where to start when treating COPD?

PROGNOSTIC IMPORTANCE OF BLOOD PRESSURE AND HEART RATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE: THE SUMMIT TRIAL

HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL

Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study

Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease

Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD

Corrigendum to “Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial” [Respir Med 107 (2013) 550–559]

Measuring habitual physical activity in adults with cystic fibrosis

Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial

Factors associated with change in exacerbation frequency in COPD

Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study

Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

Filter options

Publication date

Content availability

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Peter M.A. Calverley

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options